• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Gsk Plc ADR (NY: GSK )

    40.91 +0.11 (+0.27%)
    Streaming Delayed Price Updated: 12:20 PM EDT, Sep 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,141,552
    Open 40.96
    Bid (Size) 40.91 (4)
    Ask (Size) 40.92 (7)
    Prev. Close 40.80
    Today's Range 40.86 - 41.03
    52wk Range 33.67 - 45.92
    Shares Outstanding 5,385,189,617
    Dividend Yield 3.53%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
    Wave Life Sciences has received recent Wall Street price targets forecasting big upside. The company has a potentially "industry-leading" treatment. 
    Via MarketBeat
    Topics Economy
    Exposures Interest Rates
    Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)
    From Alector, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +9.06%
    +9.06%
    1 Month
    -4.03%
    -4.03%
    3 Month
    +0.89%
    +0.89%
    6 Month
    -4.48%
    -4.48%
    1 Year
    +8.49%
    +8.49%

    More News

    Read More
    AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
    Via Benzinga
    Exposures Product Safety
    GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
    Via Benzinga
    Exposures Product Safety
    GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
    From GSK plc
    Via Business Wire
    Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
    Via Investor's Business Daily
    Topics Death
    Exposures Death
    Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day
    Via Investor's Business Daily
    GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza mRNA Vaccine
    Via Benzinga
    GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech
    Via Benzinga
    FDA Battles Backlog of Drug Factory Inspections Since COVID-19
    Via Benzinga
    Exposures Product Safety
    GSK's Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker's Lungs, Prepares Competition With Amgen/AstraZeneca's Drug
    Via Benzinga
    Novo Nordisk's Ozempic Might Be Among 2027 Medicare Price Negotiation Targets
    Via Benzinga
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    New European Regulations Could Hinder Rare Disease Treatments, Pharma Industry Raises Concerns Over Stricter Clinical Trial Rules
    Via Benzinga
    Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
    Via Benzinga
    BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Release Promising Clinical Data As Global Alzheimer’s Disease Therapeutics Market Grows
    Via Investor Brand Network
    Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
    From Myriad Genetics, Inc.
    Via GlobeNewswire
    Lucrative Incentive for Biotechs as Global Alzheimer’s Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
    Via FinancialNewsMedia
    Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033
    From FN Media Group LLC
    Via GlobeNewswire
    Moderna Lost 27% Of Its Value Over Two Days. It Just Crumbled Again.
    Via Investor's Business Daily
    Moderna Stock Trading Lower On Dismal Guidance, Analysts Cuts Price Targets Noting Competitive Pressure From GSK, Pfizer
    Via Benzinga
    Exposures COVID-19
    US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
    From GSK plc
    Via Business Wire
    Tech Stocks On Track For Best Session In 5 Months Ahead Of Fed Meeting; Small Caps Target Highest Close Since January 2022: What's Driving Markets Wednesday?
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.